In a filing, BridgeBio Pharma Inc revealed its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $0.61 million on Nov 19 ’24. In the deal valued at $22.41 per share,27,389 shares were sold. As a result of this transaction, Kumar Neil now holds 4,897,443 shares worth roughly $137.72 million.
Then, STEPHENSON BRIAN C sold 4,156 shares, generating $93,137 in total proceeds. Upon selling the shares at $22.41, the Secretary, Treasurer & CFO now owns 93,758 shares.
Before that, BRIAN STEPHENSON bought 4,156 shares. BridgeBio Pharma Inc shares valued at $92,887 were divested by the Officer at a price of $22.35 per share.
Scotiabank initiated its BridgeBio Pharma Inc [BBIO] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”a Perform”‘ rating. Piper Sandler began covering BBIO with “an Overweight” recommendation on September 04, 2024.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -0.28% to $28.12. Over the last five days, the stock has lost -0.95%. BridgeBio Pharma Inc shares have risen nearly 2.48% since the year began. Nevertheless, the stocks have fallen -25.71% over the past one year. While a 52-week high of $41.04 was reached on 01/02/25, a 52-week low of $21.62 was recorded on 01/02/25. SMA at 50 days reached $26.12, while 200 days put it at $26.61.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 27.75, which if violated will result in even more drops to 27.39. On the upside, there is a resistance level at 28.52. A further resistance level may holdings at 28.93. The Relative Strength Index (RSI) on the 14-day chart is 55.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 24.04%. Stochastics %K at 66.25% indicates the stock is a holding.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2024-12-13, dropping by 63295.0 shares to a total of 17.12 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 17.19 million shares. There was a decline of -0.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 31, 2024 when BMO Capital Markets began covering the stock and recommended ‘”a Market perform”‘ rating along with a $37 price target.
